Transcription Factor ELK3 Promotes Stemness and Oxaliplatin Resistance of Glioma Cells by Regulating RNASEH2A

Abstract

Oxaliplatin is a member of the platinum group that is often used to treat glioma, a common type of malignant brain tumor, though it does not come with desirable and notable effects. This study attempted to investigate how ELK3 impacts the oxaliplatin resistance of glioma cells and its molecular mechanism. Bioinformatics analysis was employed to screen mRNAs with differential expression in glioma cells and predict the possible regulator downstream. We used qRT-PCR to detect the expression of ELK3 and RNASEH2A. Dual-luciferase and ChIP assays were adopted to reassure the regulatory relationship between the two. We also evaluated cell viability and sphere formation efficiency through CCK-8 and sphere formation assay and calculated the IC50 value by using CCK-8 assay. The expression of stemness-related proteins (ALDH1 and Nanog) was assessed through western blot. Glioma cells and tissues presented a significantly high expression of ELK3, the knock-down of which would reduce the cell viability, stemness and oxaliplatin resistance dramatically. Bioinformatics analysis predicted RNASEH2A to be the downstream regulator of ELK3. RNASEH2A was remarkably upregulated in glioma tissue and cells. The results from dual luciferase assay and ChIP experiment verified the binding relationship between RNASEH2A promoter region and ELK3. Then through rescue experiments, we confirmed that overexpression of RNASEH2A could compensate for the inhibition of glioma cell progression resulting from the knock-down of ELK3. ELK3 could promote stemness and oxaliplatin resistance of glioma cells by upregulating RNASEH2A, indicating that targeting ELK3/RNASEH2A axis may be a possible solution to overcome oxaliplatin resistance of glioma cells.

Key words

ELK3 - RNASEH2A - glioma cells - tumor cell stemness - oxaliplatin resistance

Publication History

Received: 16 August 2022

Accepted after revision: 09 November 2022

Article published online:
13 January 2023

• References

• 1 Hanif F, Muzaffar K, Perveen K. et al. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 2017; 18: 3-9
• 2 Khan S, Mittal S, McGee K. et al. Role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance. Int J Mol Sci 2020; 21
• 3 Osuka S, Van Meir EG. Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest 2017; 127: 415-426
• 4 Kim HI, Hong SH, Ku JM. et al. Gardenia jasminoides enhances CDDP-induced apoptosis of glioblastoma cells via AKT/mTOR pathway while protecting death of astrocytes. Nutrients 2020; 12
• 5 Zhang Z, Yin J, Lu C. et al. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. J Exp Clin Cancer Res 2019; 38: 166
• 6 Ataizi ZS, Ertilav K. Pregabalin reduces oxaliplatin-induced oxidative neurotoxicity through modulation of TRPV1 channels in DBTRG neuronal cell line. Anticancer Drugs 2020; 31: 728-736
• 7 Geng N, Shi BJ, Li SL. et al. Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells. Eur Rev Med Pharmacol Sci 2018; 22: 3826-3836
• 8 DeCordova S, Shastri A, Tsolaki AG. et al. Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma. Front Immunol 2020; 11: 1402
• 9 Nicholson JG, Fine HA. Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov 2021; 11: 575-590
• 10 Zhu T, Zheng J, Zhuo W. et al. ETV4 promotes breast cancer cell stemness by activating glycolysis and CXCR4-mediated sonic Hedgehog signaling. Cell Death Discov 2021; 7: 126
• 11 Liu YC, Yeh CT, Lin KH. Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies. Cells 2020; 9
• 12 Zhang W, Torres-Rojas C, Yue J. et al. Adipose-derived stem cells in ovarian cancer progression, metastasis, and chemoresistance. Exp Biol Med (Maywood) 2021; 246: 1810-1815
• 13 Heng WS, Gosens R, Kruyt FAE. Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting. Biochem Pharmacol 2019; 160: 121-133
• 14 Li B, Lu Y, Yu L. et al. miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-kappaB/COX-2 activation. Chem Biol Interact 2017; 277: 33-42
• 15 Wu H, Mu X, Liu L. et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis 2020; 11: 801
• 16 Annovazzi L, Mellai M, Schiffer D. Chemotherapeutic drugs: DNA damage and repair in glioblastoma. Cancers (Basel) 2017; 9
• 17 Huang W, Zhong Z, Luo C. et al. The miR-26a/AP-2alpha/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma. Theranostics 2019; 9: 5497-5516
• 18 Tang T, Wang LX, Yang ML. et al. lncRNA TPTEP1 inhibits stemness and radioresistance of glioma through miR106a5pmediated P38 MAPK signaling. Mol Med Rep 2020; 22: 4857-4867
• 19 Deng Y, Zhu H, Xiao L. et al. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis. Aging (Albany NY) 2020; 13: 2198-2211
• 20 Zhang J, Song H, Chen C. et al. Methyltransferase-like protein 11A promotes migration of cervical cancer cells via up-regulating ELK3. Pharmacol Res 2021; 172: 105814
• 21 Wang S, Li J, Yang X. Long non-coding RNA LINC00525 promotes the stemness and chemoresistance of colorectal cancer by targeting miR-507/ELK3 Axis. Int J Stem Cells 2019; 12: 347-359
• 22 Dai B, Zhang P, Zhang Y. et al. RNaseH2A is involved in human gliomagenesis through the regulation of cell proliferation and apoptosis. Oncol Rep 2016; 36: 173-180
• 23 Ahmad A, Zhang W, Wu M. et al. Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes. Genes Genomics 2018; 40: 243-251
• 24 Buchwalter G, Gross C, Wasylyk B. Ets ternary complex transcription factors. Gene 2004; 324: 1-14
• 25 Zhou L, Wu Y, Xin L. Expression characteristics and functional analysis of ELK3 in gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao 2021; 41: 1287-1295
• 26 Liu Z, Ren Z, Zhang C. et al. ELK3: A new molecular marker for the diagnosis and prognosis of glioma. Front Oncol 2021; 11: 608748
• 27 Park JH, Kim KP, Ko JJ. et al. PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy. Biochem Biophys Res Commun 2016; 477: 277-282
• 28 Zhang J, Ma D, Kang H. et al. Long noncoding RNA LINC01287 promotes proliferation and inhibits apoptosis of lung adenocarcinoma cells via the miR-3529-5p/RNASEH2A axis under the competitive endogenous RNA pattern. Environ Toxicol 2021; 36: 2093-2104
• 29 Shen J, Lin S, Liu L. et al. Ribonuclease H2 subunit A impacts invasiveness and chemoresistance resulting in poor survivability of breast cancer in ER dependent manner. Am J Transl Res 2020; 12: 2281-2294